{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T02:05:12Z","timestamp":1774663512244,"version":"3.50.1"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,8,6]],"date-time":"2018-08-06T00:00:00Z","timestamp":1533513600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2018,8,6]],"date-time":"2018-08-06T00:00:00Z","timestamp":1533513600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100007601","name":"EC | Horizon 2020","doi-asserted-by":"publisher","award":["642609"],"award-info":[{"award-number":["642609"]}],"id":[{"id":"10.13039\/501100007601","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007601","name":"EC | Horizon 2020","doi-asserted-by":"publisher","award":["642609"],"award-info":[{"award-number":["642609"]}],"id":[{"id":"10.13039\/501100007601","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003130","name":"Fonds Wetenschappelijk Onderzoek","doi-asserted-by":"publisher","award":["12Q8115N"],"award-info":[{"award-number":["12Q8115N"]}],"id":[{"id":"10.13039\/501100003130","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The growing drug resistance (DR) raises major concerns for the control of visceral leishmaniasis (VL), a neglected disease lethal in 95 percent of the cases if left untreated. Resistance has rendered antimonials (SSG) obsolete in the Indian Sub-Continent (ISC) and the first miltefosine-resistant<jats:italic>Leishmania donovani<\/jats:italic>were isolated. New chemotherapeutic options are needed and novel compounds are being identified by high-throughput screening (HTS). HTS is generally performed with old laboratory strains such as<jats:italic>LdBOB<\/jats:italic>and we aimed here to validate the activity of selected compounds against recent clinical isolates. In this academic\/industrial collaboration, 130 compounds from the GSK \u201cLeishbox\u201d were screened against one SSG-sensitive and one SSG-resistant strain of<jats:italic>L. donovani<\/jats:italic>recently isolated from ISC patients, using an intracellular assay of<jats:italic>L. donovani<\/jats:italic>-infected THP1-derived macrophages. We showed that only 45% of the compounds were active in both clinical isolates and<jats:italic>LdBOB<\/jats:italic>. There were also different compound efficiencies linked to the SSG susceptibility background of the strains. In addition, our results suggested that the differential susceptibility profiles were chemical series-dependent. In conclusion, we demonstrate the potential value of including clinical isolates (as well as resistant strains) in the HTS progression cascade.<\/jats:p>","DOI":"10.1038\/s41598-018-30040-5","type":"journal-article","created":{"date-parts":[[2018,7,31]],"date-time":"2018-07-31T14:11:28Z","timestamp":1533046288000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Importance of secondary screening with clinical isolates for anti-leishmania drug discovery"],"prefix":"10.1038","volume":"8","author":[{"given":"Aya","family":"Hefnawy","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan","family":"Cantizani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Imanol","family":"Pe\u00f1a","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pilar","family":"Manzano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suman","family":"Rijal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Claude","family":"Dujardin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2295-5564","authenticated-orcid":false,"given":"Geraldine","family":"De Muylder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julio","family":"Martin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,8,6]]},"reference":[{"key":"30040_CR1","doi-asserted-by":"publisher","first-page":"e35671","DOI":"10.1371\/journal.pone.0035671","volume":"7","author":"J Alvar","year":"2012","unstructured":"Alvar, J. et al. Leishmaniasis Worldwide and Global Estimates of Its Incidence. PLoS One 7, e35671 (2012).","journal-title":"PLoS One"},{"issue":"664","key":"30040_CR2","first-page":"666","volume":"106","author":"GPS Dhillon","year":"2008","unstructured":"Dhillon, G. P. S., Sharma, S. N. & Nair, B. Kala-azar elimination programme in India. J. Indian Med. Assoc. 106(664), 666\u20138 (2008).","journal-title":"J. Indian Med. Assoc."},{"key":"30040_CR3","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.pt.2016.11.003","volume":"33","author":"A Hefnawy","year":"2016","unstructured":"Hefnawy, A., Berg, M., Dujardin, J.-C. & De Muylder, G. Exploiting Knowledge on Leishmania Drug Resistance to Support the Quest for New Drugs. Trends Parasitol. 33, 162\u2013174 (2016).","journal-title":"Trends Parasitol."},{"key":"30040_CR4","doi-asserted-by":"publisher","first-page":"681","DOI":"10.4269\/ajtmh.2007.76.681","volume":"76","author":"MK Mittal","year":"2007","unstructured":"Mittal, M. K. et al. Characterization of natural antimony resistance in Leishmania donovani isolates. Am. J. Trop. Med. Hyg. 76, 681\u2013688 (2007).","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"30040_CR5","doi-asserted-by":"publisher","first-page":"S26","DOI":"10.1016\/j.trstmh.2006.02.011","volume":"100","author":"S Sundar","year":"2006","unstructured":"Sundar, S., Jha, T. K., Thakur, C. P., Bhattacharya, S. K. & Rai, M. Oral miltefosine for the treatment of Indian visceral leishmaniasis. Trans. R. Soc. Trop. Med. Hyg. 100, S26\u2013S33 (2006).","journal-title":"Trans. R. Soc. Trop. Med. Hyg."},{"key":"30040_CR6","doi-asserted-by":"publisher","first-page":"1530","DOI":"10.1093\/cid\/cit102","volume":"56","author":"S Rijal","year":"2013","unstructured":"Rijal, S. et al. Increasing failure of miltefosine in the treatment of Kala-azar in Nepal and the potential role of parasite drug resistance, reinfection, or noncompliance. Clin. Infect. Dis. 56, 1530\u20138 (2013).","journal-title":"Clin. Infect. Dis."},{"key":"30040_CR7","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s13071-017-1969-z","volume":"10","author":"S Srivastava","year":"2017","unstructured":"Srivastava, S. et al. Laboratory confirmed miltefosine resistant cases of visceral leishmaniasis from India. Parasit. Vectors 10, 49 (2017).","journal-title":"Parasit. Vectors"},{"key":"30040_CR8","doi-asserted-by":"publisher","first-page":"e818","DOI":"10.1371\/journal.pntd.0000818","volume":"4","author":"F Meheus","year":"2010","unstructured":"Meheus, F. et al. Cost-Effectiveness Analysis of Combination Therapies for Visceral Leishmaniasis in the Indian Subcontinent. PLoS Negl. Trop. Dis. 4, e818 (2010).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"30040_CR9","doi-asserted-by":"publisher","DOI":"10.1186\/s40249-016-0112-2","volume":"5","author":"OP Singh","year":"2016","unstructured":"Singh, O. P., Singh, B., Chakravarty, J. & Sundar, S. Current challenges in treatment options for visceral leishmaniasis in India: a public health perspective. Infect. Dis. Poverty 5, 19 (2016).","journal-title":"Infect. Dis. Poverty"},{"key":"30040_CR10","doi-asserted-by":"publisher","unstructured":"Garc\u00eda-Hern\u00e1ndez, R., Manzano, J. I., Castanys, S. & Gamarro, F. Leishmania donovani Develops Resistance to Drug Combinations. PLoS Negl. Trop. Dis. https:\/\/doi.org\/10.1371\/journal.pntd.0001974 (2012).","DOI":"10.1371\/journal.pntd.0001974"},{"key":"30040_CR11","doi-asserted-by":"publisher","first-page":"e1671","DOI":"10.1371\/journal.pntd.0001671","volume":"6","author":"JL Siqueira-Neto","year":"2012","unstructured":"Siqueira-Neto, J. L. et al. An image-based high-content screening assay for compounds targeting intracellular Leishmania donovani amastigotes in human macrophages. PLoS Negl. Trop. Dis. 6, e1671 (2012).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"30040_CR12","doi-asserted-by":"publisher","first-page":"e1253","DOI":"10.1371\/journal.pntd.0001253","volume":"5","author":"G De Muylder","year":"2011","unstructured":"De Muylder, G. et al. A Screen against Leishmania Intracellular Amastigotes: Comparison to a Promastigote Screen and Identification of a Host Cell-Specific Hit. PLoS Negl. Trop. Dis. 5, e1253 (2011).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"30040_CR13","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.ijpddr.2012.01.003","volume":"2","author":"LH Freitas-Junior","year":"2012","unstructured":"Freitas-Junior, L. H., Chatelain, E., Kim, H. A. & Siqueira-Neto, J. L. Visceral leishmaniasis treatment: What do we have, what do we need and how to deliver it? Int. J. Parasitol. Drugs Drug Resist. 2, 11\u201319 (2012).","journal-title":"Int. J. Parasitol. Drugs Drug Resist."},{"key":"30040_CR14","doi-asserted-by":"publisher","first-page":"5197","DOI":"10.1128\/AAC.00866-09","volume":"53","author":"RI da Luz","year":"2009","unstructured":"da Luz, R. I., Vermeersch, M., Dujardin, J.-C., Cos, P. & Maes, L. In vitro sensitivity testing of Leishmania clinical field isolates: preconditioning of promastigotes enhances infectivity for macrophage host cells. Antimicrob. Agents Chemother. 53, 5197\u2013203 (2009).","journal-title":"Antimicrob. Agents Chemother."},{"key":"30040_CR15","doi-asserted-by":"publisher","first-page":"e675","DOI":"10.1371\/journal.pntd.0000675","volume":"4","author":"JL Siqueira-Neto","year":"2010","unstructured":"Siqueira-Neto, J. L. et al. Antileishmanial High-Throughput Drug Screening Reveals Drug Candidates with New Scaffolds. PLoS Negl. Trop. Dis. 4, e675 (2010).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"30040_CR16","doi-asserted-by":"publisher","first-page":"e0004094","DOI":"10.1371\/journal.pntd.0004094","volume":"9","author":"A N\u00fchs","year":"2015","unstructured":"N\u00fchs, A. et al. Development and Validation of a Novel Leishmania donovani Screening Cascade for High-Throughput Screening Using a Novel Axenic Assay with High Predictivity of Leishmanicidal Intracellular Activity. PLoS Negl. Trop. Dis. 9, e0004094 (2015).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"30040_CR17","doi-asserted-by":"publisher","first-page":"3524","DOI":"10.1128\/AAC.01781-15","volume":"60","author":"D Tegazzini","year":"2016","unstructured":"Tegazzini, D. et al. A Replicative In Vitro Assay for Drug Discovery against Leishmania donovani. Antimicrob. Agents Chemother. 60, 3524\u201332 (2016).","journal-title":"Antimicrob. Agents Chemother."},{"key":"30040_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/srep08771","volume":"5","author":"I Pe\u00f1a","year":"2015","unstructured":"Pe\u00f1a, I. et al. New compound sets identified from high throughput phenotypic screening against three kinetoplastid parasites: an open resource. Sci. Rep. 5, 8771 (2015).","journal-title":"Sci. Rep."},{"key":"30040_CR19","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0166-6851(03)00142-7","volume":"130","author":"S Goyard","year":"2003","unstructured":"Goyard, S. et al. An in vitro system for developmental and genetic studies of Leishmania donovani phosphoglycans. Mol. Biochem. Parasitol. 130, 31\u201342 (2003).","journal-title":"Mol. Biochem. Parasitol."},{"key":"30040_CR20","doi-asserted-by":"publisher","first-page":"3855","DOI":"10.1128\/AAC.00548-09","volume":"53","author":"M Vermeersch","year":"2009","unstructured":"Vermeersch, M. et al. In vitro susceptibilities of Leishmania donovani promastigote and amastigote stages to antileishmanial reference drugs: practical relevance of stage-specific differences. Antimicrob. Agents Chemother. 53, 3855\u20139 (2009).","journal-title":"Antimicrob. Agents Chemother."},{"key":"30040_CR21","unstructured":"Landqvist, C., Middleton, B. Jones, B. & O\u2019Donnell, C. A novel approach by AstraZeneca to monitor primary DMPK assay performance & understand the inter and intra site assay variability. At http:\/\/www.ddw-online.com\/drug-discovery\/p218111-a-novel-approach-by-astrazeneca-to-monitor-primary-dmpk-assay-performance-&-understand-the-inter-and-intra-site-assay-variabilityfall-14.html (2014)."},{"key":"30040_CR22","unstructured":"Heidelberg, E. Assay validation, performance and quality control Computational Aspects of High-Throughput Screening planning and analysis. At http:\/\/www.biomedbridges.eu\/sites\/biomedbridges.eu\/files\/training\/9_-_david_murray_-_assay_validation.pdf (2013)."},{"key":"30040_CR23","doi-asserted-by":"publisher","first-page":"e0005629","DOI":"10.1371\/journal.pntd.0005629","volume":"11","author":"D Tegazzini","year":"2017","unstructured":"Tegazzini, D., Cantizani, J., Pe\u00f1a, I., Mart\u00edn, J. & Coter\u00f3n, J. M. Unravelling the rate of action of hits in the Leishmania donovani box using standard drugs amphotericin B and miltefosine. PLoS Negl. Trop. Dis. 11, e0005629 (2017).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"30040_CR24","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.meegid.2011.11.005","volume":"12","author":"T Downing","year":"2012","unstructured":"Downing, T. et al. Genome-wide SNP and microsatellite variation illuminate population-level epidemiology in the Leishmania donovani species complex. Infect. Genet. Evol. 12, 149\u201359 (2012).","journal-title":"Infect. Genet. Evol."},{"key":"30040_CR25","doi-asserted-by":"publisher","first-page":"e855","DOI":"10.1371\/journal.pntd.0000855","volume":"4","author":"AM Musa","year":"2010","unstructured":"Musa, A. M. et al. Paromomycin for the treatment of visceral leishmaniasis in Sudan: a randomized, open-label, dose-finding study. PLoS Negl. Trop. Dis. 4, e855 (2010).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"30040_CR26","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1016\/j.ijpara.2011.07.013","volume":"41","author":"R Mukhopadhyay","year":"2011","unstructured":"Mukhopadhyay, R. et al. Characterisation of antimony-resistant Leishmania donovani isolates: biochemical and biophysical studies and interaction with host cells. Int. J. Parasitol. 41, 1311\u201321 (2011).","journal-title":"Int. J. Parasitol."},{"key":"30040_CR27","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1111\/mmi.12374","volume":"90","author":"M Berg","year":"2013","unstructured":"Berg, M. et al. Metabolic adaptations of Leishmania donovani in relation to differentiation, drug resistance, and drug pressure. Mol. Microbiol. 90, 428\u2013442 (2013).","journal-title":"Mol. Microbiol."},{"key":"30040_CR28","doi-asserted-by":"publisher","first-page":"E575","DOI":"10.1073\/pnas.1213839110","volume":"110","author":"B Mukherjee","year":"2013","unstructured":"Mukherjee, B. et al. Antimony-resistant but not antimony-sensitive Leishmania donovani up-regulates host IL-10 to overexpress multidrug-resistant protein 1. Proc. Natl. Acad. Sci. USA 110, E575\u201382 (2013).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"30040_CR29","doi-asserted-by":"publisher","first-page":"e12211","DOI":"10.1371\/journal.pone.0012211","volume":"5","author":"M Vanaerschot","year":"2010","unstructured":"Vanaerschot, M. et al. Linking In Vitro and In Vivo Survival of Clinical Leishmania donovani Strains. PLoS One 5, e12211 (2010).","journal-title":"PLoS One"},{"key":"30040_CR30","first-page":"236","volume":"47","author":"M Banjanac","year":"2009","unstructured":"Banjanac, M., Tatic, I., Ivezic, Z., Tomic, S. & Dumic, J. Pyrimido-Pyrimidines: A Novel Class of Dihydrofolate Reductase Inhibitors. Food Technol. Biotechnol. 47, 236\u2013245 (2009).","journal-title":"Food Technol. Biotechnol."},{"key":"30040_CR31","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1016\/j.bmcl.2013.12.022","volume":"24","author":"F Mjambili","year":"2014","unstructured":"Mjambili, F. et al. Synthesis and biological evaluation of 2-aminothiazole derivatives as antimycobacterial and antiplasmodial agents. Bioorg. Med. Chem. Lett. 24, 560\u20134 (2014).","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"30040_CR32","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1128\/AAC.01788-12","volume":"57","author":"S Wyllie","year":"2013","unstructured":"Wyllie, S., Patterson, S. & Fairlamb, A. H. Assessing the Essentiality of Leishmania donovani Nitroreductase and Its Role in Nitro Drug Activation. Antimicrob. Agents Chemother. 57, 901\u2013906 (2013).","journal-title":"Antimicrob. Agents Chemother."},{"key":"30040_CR33","doi-asserted-by":"crossref","unstructured":"Synthesis of 2-[3,5-substituted pyrazol-1-yl]-4,6-trisubstituted triazine derivatives as antimalarial agents. Bioorg. Med. Chem. Lett. 15, 4957\u20134960 (2005).","DOI":"10.1016\/j.bmcl.2005.08.023"},{"key":"30040_CR34","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.trstmh.2007.09.003","volume":"102","author":"M Boelaert","year":"2008","unstructured":"Boelaert, M. et al. Diagnostic tests for kala-azar: a multi-centre study of the freeze-dried DAT, rK39 strip test and KAtex in East Africa and the Indian subcontinent. Trans. R. Soc. Trop. Med. Hyg. 102, 32\u201340 (2008).","journal-title":"Trans. R. Soc. Trop. Med. Hyg."},{"key":"30040_CR35","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.4269\/ajtmh.13-0759","volume":"91","author":"A Bezuneh","year":"2014","unstructured":"Bezuneh, A. et al. Comparison of point-of-care tests for the rapid diagnosis of visceral leishmaniasis in East African patients. Am. J. Trop. Med. Hyg. 91, 1109\u201315 (2014).","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"30040_CR36","doi-asserted-by":"publisher","first-page":"e2057","DOI":"10.1371\/journal.pntd.0002057","volume":"7","author":"T Bhattacharyya","year":"2013","unstructured":"Bhattacharyya, T., Boelaert, M. & Miles, M. A. Comparison of Visceral Leishmaniasis Diagnostic Antigens in African and Asian Leishmania donovani Reveals Extensive Diversity and Region-specific Polymorphisms. PLoS Negl. Trop. Dis. 7, e2057 (2013).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"30040_CR37","doi-asserted-by":"publisher","first-page":"2913","DOI":"10.1128\/AAC.02398-12","volume":"57","author":"M De Rycker","year":"2013","unstructured":"De Rycker, M. et al. Comparison of a high-throughput high-content intracellular Leishmania donovani assay with an axenic amastigote assay. Antimicrob. Agents Chemother. 57, 2913\u201322 (2013).","journal-title":"Antimicrob. Agents Chemother."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-30040-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-30040-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-30040-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,8]],"date-time":"2024-07-08T20:44:25Z","timestamp":1720471465000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-30040-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,6]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,12]]}},"alternative-id":["30040"],"URL":"https:\/\/doi.org\/10.1038\/s41598-018-30040-5","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8,6]]},"assertion":[{"value":"23 January 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"11765"}}